Reviva Pharma gains as H.C. Wainwright initiates with 'buy'

Reviva Pharmaceuticals Holdings

24/01/2022 12:42

** Shares of drug developer  RVPH.O  rise 6.9% to $1.85
premarket after H.C. Wainwright starts coverage with "buy"
rating and $10 PT 
    ** Brokerage believes co's development of "brilaroxazine", a
antipsychotic agent, gives the co a highly advantageous
pharmacological profile
    ** Adds that clinical data positions "brilaroxazine"
favorably and provides a solid rationale for progression into
pivotal development
    ** Believes co's plans to advance brilaroxazine into a
pivotal phase 3 program could act as near- and medium-term
catalysts for stock performance  
    ** Up to Friday's close, stock had fallen ~40% YTD

 (Reporting by Amal S in Bengaluru)
 ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780;
outside U.S. +91 80 6749 3677;))